

REMARKS

The generic claims have been cancelled without prejudice to expedite allowance.

The compounds of claims 15 and 41 are supported by Table 1 on pages 129-130 of the specification. Compound 98 of the Table has been cancelled without prejudice. The potency data presented in Table 1 demonstrate that these compounds are effective in the methods of the claimed invention. The compound structures are not obvious from the compounds of the cited USP '249.

In view of the foregoing, the rejection of the former claims on the ground of obviousness-type double patenting over USP '249 is deemed to be overcome.

The double patenting rejection on the basis of Serial No. 11/478,218 is overcome because this application has been abandoned.

The double patenting rejections based upon Serial No. 11/997,786 and Serial No. 12/071,807 should be withdrawn as the present application has an earlier filing date.

In view of the foregoing, it is believed that each ground of rejection set forth in the Official Action has been overcome, and that the application is now in condition for allowance. Accordingly, such allowance is solicited.

Respectfully submitted,

Brian A. JOHNS et al.

By: Warren M. Cheek
Warren M. Cheek
Registration No. 33,367
Attorney for Applicants

WMC/dlk
Washington, D.C. 20006-1021
Telephone (202) 721-8200
Facsimile (202) 721-8250
December 14, 2009